Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabiae in Patients with Relapsed/Refractory AML

被引：0
|
作者：
Schimmer, Aaron D. [1 ]
Estey, Elihu H. [7 ]
Borthakur, Gautam [7 ]
Carter, Bing [7 ]
Schiller, Gary J. [2 ]
Tallman, Martin S. [3 ]
Altman, Jessica K. [3 ]
Karp, Judith E. [4 ]
Kassis, Jeannine [5 ]
Jacob, Christine [6 ]
Morris, Stephen [6 ]
Jolivet, Jacques [6 ]
Andreeff, Michael [7 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada
[6] Aegera Therapeut Inc, Montreal, PQ, Canada
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：283 / 284
页数：2
相关论文
共 50 条
  • [1] Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.
    Carter, Bing Z.
    Mak, Duncan H.
    Morris, Stephen
    Borthakur, Gautam
    Estey, Elihu
    Byrd, Anna L.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Andreeff, Michael
    BLOOD, 2008, 112 (11) : 678 - 678
  • [2] XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML
    Bing Z. Carter
    Duncan H. Mak
    Stephen J. Morris
    Gautam Borthakur
    Elihu Estey
    Anna L. Byrd
    Marina Konopleva
    Hagop Kantarjian
    Michael Andreeff
    Apoptosis, 2011, 16 : 67 - 74
  • [3] XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML
    Carter, Bing Z.
    Mak, Duncan H.
    Morris, Stephen J.
    Borthakur, Gautam
    Estey, Elihu
    Byrd, Anna L.
    Konopleva, Marina
    Kantarjian, Hagop
    Andreeff, Michael
    APOPTOSIS, 2011, 16 (01) : 67 - 74
  • [4] Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
    Mahadevan, Daruka
    Chalasani, Pavani
    Rensvold, Diane
    Kurtin, Sandy
    Pretzinger, Chris
    Jolivet, Jacques
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Weiss, Glen J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (03): : 239 - 243
  • [5] Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
    Schimmer, Aaron D.
    Estey, Elihu H.
    Borthakur, Gautam
    Carter, Bing Z.
    Schiller, Gary J.
    Tallman, Martin S.
    Altman, Jessica K.
    Karp, Judith E.
    Kassis, Jeannine
    Hedley, David W.
    Brandwein, Joseph
    Xu, Wei
    Mak, Duncan H.
    LaCasse, Eric
    Jacob, Christine
    Morris, Stephen J.
    Jolivet, Jacques
    Andreeff, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4741 - 4746
  • [6] A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.
    Ranson, M.
    Dive, C.
    Ward, T.
    Cummings, J.
    Connolly, K.
    Evans, S.
    Robson, L.
    Durkin, J.
    Jolivet, J.
    Jodrell, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 135S - 135S
  • [7] A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours
    Jolivet, J.
    Dean, E.
    Ward, T. H.
    Denneny, O.
    Jacob, C.
    Goodege, P.
    Dive, C.
    Ranson, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients
    Lacasse, Eric
    Morris, Stephen
    Ward, Tim
    Cumings, Jeff
    Robson, Lesley
    Di Tullio, Katrina
    Methot, Danielle
    Jerome, Lori
    Winocour, Peter
    Gillard, John W.
    Jolivet, Jacques
    Jodrell, Duncan
    Ranson, Malcolm
    Durkin, Jon
    CANCER RESEARCH, 2006, 66 (08)
  • [9] Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study
    Schimmer, Aaron D.
    Herr, Wolfgang
    Haenel, Mathias
    Borthakur, Gautham
    Frankel, Arthur
    Horst, Heinz-August
    Martin, Sonja
    Kassis, Jeannine
    Desjardins, Pierre
    Seiter, Karen
    Fiedler, Walter
    Noppeney, Richard
    Giagounidis, Aristoteles
    Jacob, Christine
    Jolivet, Jacques
    Tallman, Martin S.
    Koschmieder, Steffen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (05): : 433 - 438
  • [10] A phase I trial of AEG35156 (XIAP antisense) administered as a 7-day continuous intravenous infusion in patients with advanced tumors.
    Ranson, M
    Dive, C
    Ward, T
    Cummings, J
    Connolly, K
    Evans, S
    Robson, L
    Durkin, J
    Jolivet, J
    Jodrell, D
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9117S
12345